Terns Pharma Stock (NASDAQ:TERN), Analyst Ratings, Price Targets, Predictions

The latest price target for Terns Pharma (NASDAQ: TERN) was reported by HC Wainwright & Co. on April 30, 2024. The analyst firm set a price target for $5.50 expecting TERN to fall to within 12 months (a possible -4.51% downside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Terns Pharma (NASDAQ: TERN) was provided by HC Wainwright & Co., and Terns Pharma reiterated their neutral rating.

There is no last upgrade for Terns Pharma.

The last downgrade for Terns Pharmaceuticals Inc happened on March 23, 2022 when JP Morgan changed their price target from $19 to $6 for Terns Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Terns Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Terns Pharma was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.

While ratings are subjective and will change, the latest Terns Pharma (TERN) rating was a reiterated with a price target of $0.00 to $5.50. The current price Terns Pharma (TERN) is trading at is $5.76, which is out of the analyst’s predicted range.